(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541234

過敏性腸症候群治療市場レポート：タイプ、製品、流通チャネル、地域別、2024年～2032年

Irritable Bowel Syndrome Treatment Market Report by Type (IBS with Diarrhea, IBS with Constipation, Mixed IBS), Product, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 143 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
過敏性腸症候群治療市場レポート：タイプ、製品、流通チャネル、地域別、2024年～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の過敏性腸症候群治療市場規模は2023年に27億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに55億米ドルに達し、2024年から2032年の間に8％の成長率（CAGR）を示すと予測しています。

市場規模 年平均成長率（CAGR）グラフ | 過敏性腸症候群治療市場レポート：タイプ、製品、流通チャネル、地域別、2024年～2032年

過敏性腸症候群（IBS）は、大腸に影響を及ぼす慢性的な病状を指します。通常、重度の感染症、ストレスの多いライフスタイル、腸内微生物の変化、腸の筋収縮、神経系の異常によって引き起こされます。ガス、下痢、けいれん、腹部膨満感、便秘、体重減少、嘔吐、腹痛、嚥下障害を特徴とします。現在、リファキシミン、ロペラミド、下剤、鎮痙剤、食物繊維サプリメント、コーティングされたペパーミントオイルカプセルなど、IBSの軽い症状を和らげる薬がいくつか販売されています。医師はまた、特定の患者を治療するために、プロバイオティクスや、認知行動療法（CBT）、腸主導型催眠療法、リラクセーション・トレーニングなどのメンタルヘルス療法を推奨しています。

過敏性腸症候群治療市場傾向：

食物の不耐性や過敏性、消化管内の細菌感染、小腸細菌の過剰増殖、不安や抑うつ、身体症状などの精神障害など、いくつかの要因がIBS疾患のリスクを高める。このことは、診断方法の改善やヘルスケアサービスへの容易なアクセスとともに、市場の成長を後押しする重要な要因の一つとなっています。さらに、IBSは高齢者の間で最も一般的な機能性胃腸障害のひとつです。これに伴い、世界中で高齢者人口が増加しており、市場にプラスの影響を与えています。このほか、便微生物叢移植（FMT）など、IBSの治療を改善するための臨床試験がいくつか実施されており、これが市場の成長に寄与しています。これに加えて、持続可能な開発目標（SDGs）の一環として、各国の政府機関は2030年までに研究開発（R&D）プロジェクトと研究者数への支出を大幅に増やすことを約束しています。その結果、IBSに対する潜在的な治療選択肢の数が将来的に拡大すると予測されています。

本レポートで扱う主な質問

  • 世界の過敏性腸症候群治療市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19は世界の過敏性腸症候群治療市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • タイプ別の市場内訳は？
  • 製品別の市場内訳は？
  • 流通チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の過敏性腸症候群治療市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の過敏性腸症候群治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 下痢を伴うIBS（IBS-D）
    • 市場動向
    • 市場予測
  • 便秘を伴うIBS（IBS-C）
    • 市場動向
    • 市場予測
  • 混合型IBS
    • 市場動向
    • 市場予測

第7章 市場内訳：製品別

  • リファキシミン
    • 市場動向
    • 市場予測
  • エルクサドリン
    • 市場動向
    • 市場予測
  • ルビプロストン
    • 市場動向
    • 市場予測
  • リナクロチド
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • ドラッグストアと薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Allergan plc（AbbVie Inc.）
    • Ardelyx Inc.
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bausch Health Companies Inc.
    • GlaxoSmithKline Plc
    • Novartis AG
    • Sebela Pharmaceuticals Inc.
    • Synthetic Biologics Inc.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Irritable Bowel Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Irritable Bowel Syndrome Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Irritable Bowel Syndrome Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Irritable Bowel Syndrome Treatment (IBS with Diarrhea (IBS-D)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Irritable Bowel Syndrome Treatment (IBS with Diarrhea (IBS-D)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Irritable Bowel Syndrome Treatment (IBS with Constipation (IBS-C)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Irritable Bowel Syndrome Treatment (IBS with Constipation (IBS-C)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Irritable Bowel Syndrome Treatment (Mixed IBS) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Irritable Bowel Syndrome Treatment (Mixed IBS) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Irritable Bowel Syndrome Treatment (Rifaximin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Irritable Bowel Syndrome Treatment (Rifaximin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Irritable Bowel Syndrome Treatment (Eluxadoline) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Irritable Bowel Syndrome Treatment (Eluxadoline) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Irritable Bowel Syndrome Treatment (Lubiprostone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Irritable Bowel Syndrome Treatment (Lubiprostone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Irritable Bowel Syndrome Treatment (Linaclotide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Irritable Bowel Syndrome Treatment (Linaclotide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Irritable Bowel Syndrome Treatment (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Irritable Bowel Syndrome Treatment (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Irritable Bowel Syndrome Treatment (Hospitals Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Irritable Bowel Syndrome Treatment (Hospitals Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Irritable Bowel Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Irritable Bowel Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Irritable Bowel Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Irritable Bowel Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Irritable Bowel Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Irritable Bowel Syndrome Treatment Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Irritable Bowel Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Irritable Bowel Syndrome Treatment Industry: SWOT Analysis
  • Figure 80: Global: Irritable Bowel Syndrome Treatment Industry: Value Chain Analysis
  • Figure 81: Global: Irritable Bowel Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Irritable Bowel Syndrome Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Irritable Bowel Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Irritable Bowel Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Irritable Bowel Syndrome Treatment Market: Key Players
目次
Product Code: SR112024A4297

The global irritable bowel syndrome treatment market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 8% during 2024-2032.

Irritable bowel syndrome (IBS) refers to a chronic medical condition that affects the large intestine. It is usually caused by severe infection, stressful lifestyle, changes in gut microbes, muscle contractions in the intestine, and abnormalities in the nervous system. It can be characterized by gas, diarrhea, cramping, bloating, constipation, weight loss, vomiting, abdominal pain, and difficulty in swallowing. Several medications are currently available to relieve mild symptoms of IBS, including rifaximin, loperamide, laxatives, antispasmodics, fiber supplements, and coated peppermint oil capsules. Doctors also recommend probiotics and mental health therapies, such as cognitive behavioral-therapy (CBT), gut-directed hypnotherapy, and relaxation training, to treat certain patients

Irritable Bowel Syndrome Treatment Market Trends:

Several factors increase the risk of IBS diseases, including food intolerances or sensitivities, bacterial infections in the digestive tract, small intestinal bacterial overgrowth, and mental disorders like anxiety, depression, and somatic symptom. This, along with improving diagnostic modalities and easy access to healthcare services, represents one of the key factors bolstering the growth of the market. Furthermore, IBS is one of the most common functional gastrointestinal disorders among the elderly. In confluence with this, the rising geriatric population across the globe is influencing the market positively. Besides this, several clinical trials, such as fecal microbiota transplantation (FMT), are being conducted to improve the treatment of IBS, which is contributing to market growth. In addition to this, as part of the Sustainable Development Goals (SDGs), governing agencies of various countries have pledged to substantially increase spending on research and development (R&D) projects and the number of researchers by 2030. This, in turn, is projected to expand the number of potential treatment options for IBS in the future.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global irritable bowel syndrome treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product and distribution channel.

Breakup by Type:

IBS with Diarrhea (IBS-D)

IBS with Constipation (IBS-C)

Mixed IBS

Breakup by Product:

Rifaximin

Eluxadoline

Lubiprostone

Linaclotide

Others

Breakup by Distribution Channel:

Hospitals Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Allergan plc (AbbVie Inc.), Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, Bausch Health Companies Inc., GlaxoSmithKline Plc, Novartis AG, Sebela Pharmaceuticals Inc., Synthetic Biologics Inc. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global irritable bowel syndrome treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global irritable bowel syndrome treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global irritable bowel syndrome treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Irritable Bowel Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 IBS with Diarrhea (IBS-D)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 IBS with Constipation (IBS-C)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Mixed IBS
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Rifaximin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Eluxadoline
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Lubiprostone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Linaclotide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Allergan plc (AbbVie Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Ardelyx Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Astellas Pharma Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 AstraZeneca plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Bausch Health Companies Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline Plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sebela Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Synthetic Biologics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis